LLY Stock Recent News
LLY LATEST HEADLINES
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Demand is high for Eli Lilly's Zepbound, and the weight-loss drug market could reach $100 billion by the end of the decade. But one thing is getting in between some potential patients and this promising drug.
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.
Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines.
Eli Lilly and Novo Nordisk are two of the big names in healthcare focused on a hot GLP-1 drug market. But there's a drug from a smaller biotech which could also prove to be a big player in this area.
The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.
Eli Lilly has crushed the S&P 500 over the last 12 months and could continue delivering outsized returns. Novo Nordisk's strong fundamentals and solid growth opportunities make it a no-brainer buy.
Super Micro Computer (SMCI), Eli Lilly (LLY), and Netflix (NFLX) are today's big three stocks. Joel Hawthorne and Ben Lichtenstein discuss how to trade, as well as the technical trends of these names.
Looking ahead to the pharmaceutical earnings season, UBS expressed cautious optimism when looking at several major names. Notably, Eli Lilly and Co (NYSE:LLY), with a 'buy' rating and a price target of $910, is expected to see mixed performance due to shortages of its weightloss drig Mounjaro and Zepbound, though early stocking could partially offset declines in Trulicity sales.